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Abstract 
Activin A receptor, type II-like kinase 1 (ALK1 is a 
serine-threonine kinase) predominantly expressed 
on endothelial cells surface. Mutations in its 
ACVRL1 encoding gene (12q11-14) cause type 2 
Hereditary Haemorrhagic Telangiectasia (HHT2), 
an autosomal dominant multisystem vascular 
dysplasia. Its involvement in cancer 
neoangiogenesis has lead to the recent development 
of novel anti-cancer drugs, which are now in 
clinical trials. 
Identity 
Other names: ACVRLK1, ALK-1, ALK1, HHT, 
HHT2, ORW2, SKR3, TSR-I 
HGNC (Hugo): ACVRL1 
Location: 12q13.13 
DNA/RNA 
Note 
Starts at 52300692 and ends at 52307134 bp from 
pter (according to hg19- Feb_2009). 
Description 
ACVRL1 is a protein coding gene and in human it 
is constituted by 10 exons. All exons but the first 
are coding exons. ACVRL1 transcript variants 
mRNA3 and mRNA4 include 11 exons, through the 
presence of a cryptic non-translated exon upstream 
of the canonical exon 1 (Garrido-Martin et al., 
2010). 
Transcription 
Gene database underlines the presence of two 
different ACVRL1 transcripts, which both translate 
into the same protein isoform. The second transcript 
variant is the shortest one and differs from the first 
one in the 5'UTR region, due to the presence of an 
upstream in-frame start codon, poorly conserved in 
the population. Nevertheless, in 2010 two new 
transcripts were discovered in HUVEC cells. These 
new variants, called mRNA3 and mRNA4, begin 
the transcription +1 nucleotide upstream , 
respectively at -510 and -470 positions, adding a 
cryptic non translated exon, that doesn't affect the 
protein ORF (Garrido-Martin et al., 2010).  
The promoter region of ACVRL1 (5' proximal 
region: -1035/+210) was characterized by Garrido-
Martin et al., 2010. This region lacks TATA/CAAT 
boxes but contains a high number of GC-rich Sp1 
consensus sites. It also shares different putative 
regulatory elements with other endothelial-specific 
genes. These motifs includes: Ets (E26-
Transformation-Specific), KLF (Krüppel-Like 
Factor), NFkB (Nuclear Factor kappa-light-chain-
enhancer of activated B cells), E2F (Elongation 
Factor 2), one Smad binding element (SBE), RXR 
(Retinoid X Receptor) and HIF (Hypoxia Inducible 
Factor). Moreover, the authors demonstrated that 
methylation status of CpG islands modulates Sp1 
transcription of ACVRL1 in endothelial cells. 
In 2013, it has been demonstrated that ubiquitin E3 
ligase, EDD, can down-regulate ACVRL1 
expression in HeLa and HUVEC cells (Chien et al., 
2013). 
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Protein 
Description 
Activin A receptor, type II-like kinase 1 (also called 
ALK1, Uniprot entry P37023, protein family 
(pfam) 01064 of Activin types I and II receptor 
domains), is a serine-threonine kinase and it acts as 
a type I receptor for the Transforming Growth 
Factor-β / Bone Morphogenetic Protein (TGF-
β/BMP) superfamily of ligands. It includes 503 
amino acids, with residues 1-21 forming a leader 
sequence which targets the protein to the 
membrane. The extracellular domain includes 
amino acids 22-118 and it is followed by a 23 
amino acid long transmembrane domain (residues 
119-141). The intracellular domain comprises 
residues 142-503, with a GS domain (residues 172-
201) and the protein kinase domain (residues 202-
492). 
The crystal structure of ALK1 ectodomain (Figure 
1a) and of the intracellular kinase domain (Figure 
1b) have been recently determined (PDB ID: 4FAO 
and 3MY0, respectively) (Townson et al., 2012). 
Like all type I and type II receptors, ALK1 shows a 
general fold resembling a class of neurotoxins 
known as three-finger toxins and hence called 
"three-finger toxin fold". This fold is comprised 
from β-strands stabilised by disulphide bonds 
formed by conserved Cys residues. Three pairs of 
anti-parallel β-strands are curved to generate a 
concave surface. Despite the common architecture 
and the cluster of conserved Cys residues, very 
little sequence identity and no functional overlap 
exist between the two types of receptors. 
BMPs consist of a Cys knot characterised by three 
pairs of highly conserved disulphide bonds in 
which one traverses through a ring formed by the 
other 2. This fold can be described as a hand with a 
concave palm side and two parallel β-sheet forming 
4 fingers, with each β-strand being likened to a 
finger. Finger 2 leads to a helix "wrist" region. In 
the dimeric ligand the 4 fingers extend from the 
Cys core of the protein like butterfly wings. 
Binding of type I receptors occurs near the α-helix 
on the concave side at the junction between the two 
subunits (Kirsch et al., 2000), whereas binding to 
type II receptors happens on the convex side of the 
hand near the "fingertips" (Greenwald et al., 2003; 
Thompson et al., 2003). 
Expression 
ALK1 is predominantly expressed on the 
endothelial cells surface of arteries. According to 
EBI gene expression database, ALK1 levels are 
reduced in non-small cell lung cancer tissue, and 
increased in monocytes exposed to infections by 
Francisella tularensis novocida and by 
Porphyromonas gengivalis. 
 
Figure 1: Structures of ALK1 ectodomain (a) and of the 
kinase domain (b). 
Function 
ALK1 activation, triggered by its physiological 
ligand BMP-9, can be pro-angiogenic or anti-
angiogenic, depending on the experimental system 
considered. Thus, inhibition of primary cells 
(HMVEC-D, HUVEC and endothelial cells) 
proliferation was observed upon activation of the 
receptor, suggesting that this signaling pathway is 
involved in the resolution phase of angiogenesis, 
during which endothelial cell proliferation and 
migration stop. Disruption of the pathway would 
therefore lead to persistent proliferation of 
endothelial cells with the lack of a correct 
morphogenesis. 
On the other hand, MESEC (mouse embryonic- 
stem-cell-derived endothelial cells) and MEEC 
(mouse embryonic endothelial cells) cells are 
stimulated to proliferate by ALK1 activation and 
BMP9 stimulates angiogenesis in a matrigel plug 
assay and in a tumour model in vivo. Also, cancer 
cells produced tumours whose size and 
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vascularization were reduced by 50% in ALK1+/- 
heterozygous mice compared with tumours 
implanted in wild-type littermates.  
In addition, a soluble ALK1-Fc fusion protein 
known as Dalantercept (ACE-041) showed an anti-
angiogenic effect by reducing vascular density and 
perfusion of the tumour burden in model mice of 
endocrine pancreatic tumorigenesis and mice 
bearing 786-0 and A498 human renal cell 
carcinoma (Wang et al., 2012). 
This contradictory findings may be explained by 
the site- and context-dependent balance of the 
synergic proangiogenic effects of BMP-9 and the 
lower affinity ALK1 ligand TGF-β, but the 
assumption has to be confirmed. 
Recent studies also report a role for ALK1 in cancer 
independent from its effects on angiogenesis, 
enhancing the cell migration and invasion potential 
in cancers like squamous cell carcinomas of the 
head and the neck or haepatocarcinomas (Hu-Lowe 
et al., 2011; Chien et al., 2013; Sun et al., 2013). 
ALK1 signalling through SMAD 1/SMAD 
5/SMAD 8 seems to induce chondrocytes 
hypertrophy in cartilages by an effect mediated by 
the interaction with the canonical Wnt signaling 
(van den Bosch et al., 2014). 
Again, in other kind of cancers ALK1 activation 
seems to be protective, as assessed for instance in in 
vitro models of pancreatic cancers (Ungefroren et 
al., 2007). 
Homology 
ALK1 shares with other type I receptors a high 
degree of similarity in the GS domain, in the 
following serine-threonine kinase subdomains and 
in the short C-terminal tail (ten Dijke et al., 1994), 
but the extracellular domain shows a peculiar amino 
acidic sequence. 
Mutations 
Germinal 
Mutations in the ACVRL1 gene result in Hereditary 
Hemorrhagic Telangiectasia Type 2 (HHT2). A 
germinal mosaic with two mutant alleles in 
hereditary hemorrhagic telangiectasia associated 
with pulmonary arterial hypertension was described 
(Eyries et al., 2011).  
A germline heterozygous ACVRL1 polymorphisms 
(p. A482V) has been reported in a patient with a 
gonadotroph pituitary tumour by D'Abronzo et al., 
1999. 
Somatic 
No somatic mutations of ACVRL1 have been found 
in human cancers. 
 
 
 
Implicated in 
Solid tumours 
Note 
As a receptor mainly expressed on the surface of 
endothelial cells, ALK1 overexpression and 
unbalances in its signalling are implicated in many 
solid tumours, despite the origin and specific 
features of the latter. Thus, they will be discussed in 
a single paragraph. 
In a study (Hu-Lowe et al., 2011) performed on 
3000 human tumour specimens representing more 
than 100 tumour types, ALK1 resulted particularly 
expressed in the vasculature of prostate cancers, 
malignant melanomas of the skin, follicular cancers 
of the tyroid, renal clear cell cancers and 
endometrioid ovarian cancers.  
A reduced expression of ACVRL1 by qRT-PCR 
and immunohistochemistry was demonstrated in 
nasopharingeal carcinomas by Zhang et al., 2012.  
An increased ALK1 expression in papillary thyroid 
carcinomas with bone formation was increased if 
compared to that in normal thyroid tissue and 
tumors without bone formation, as assessed using 
immunohistochemistry and quantitative real-time 
polymerase chain reaction (Na et al., 2013).  
In Head and Neck Squamous Cell Carcinomas 
(HNSCC), using immunohistochemistry and qRT-
PCR, Chien et al. found a correlation between a 
high ACVRL1 expression and an advanced T 
classification, a positive N classification, an 
advanced TNM stage, the presence of 
lymphovascular invasion, an extracapsular spread 
of lymph node metastasis and a poorer prognosis 
(Chien et al., 2013). 
As a therapeutic target, anti-ALK1 drugs (both in 
the form of an Fc-fusion protein acting as a soluble 
receptor for BMP9 and of an anti-ALK1 
monoclonal antibody) are under investigation in 
phase I and phase II clinical trials in a wide range of 
solid tumours (Vecchia et al., 2013). Phase II 
studies clinical trials encompass particularly 
squamous cell carcinoma of the head and neck, 
endometrial cancer, epithelial ovarian cancer, 
fallopian tube cancer and primary peritoneal 
carcinoma for ACE-041 (also known as 
Dalantercept, the Fc-receptor fusion protein). 
Dalantercept displayed promising antitumour 
activity particularly in patients with advanced 
refractory cancer (Bendell et al., 2014). PF-
03446962 (the anti-ALK1 monoclonal antibody), is 
up to now studied in phase II clinical trials 
particularly in malignant mesoteliomas of the 
pleura and transitional cell carcinomas of the 
bladder.  
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A recent study showed that PF-03446962 has no 
activity as a single drug in refractory urothelial 
cancer as is thus suggested, for this kind of cancer, 
only as a combination therapy with other agents 
against the VEGF receptor axis (Necchi et al., 
2014). Both Dalantercept and PF-03446962 are 
currently under investigation in phase II trials 
particularly in advanced and refractory 
hepatocarcinomas. 
As assessed by Hosman et al., 2013, mutations in 
ACVRL1 gene, as the ones observed in HHT2 
patients, seem to reduce the prevalence of some 
types of solid tumours and account for the 
unexpected good life expectancy of HHT patients 
older than 60 years of age.  
Although it is important to take with care the results 
of the study due to the methodology used for the 
assessment (for the statistical and logistic 
difficulties to perform a longitudinal study in a rare 
disease, the authors used a questionnaire, inevitably 
biased), HHT patients older than 60 presented an 
apparent reduction in lung, liver and colorectal 
cancer compared to controls.  
This could potentially be related to the ALK1 
haploinsuffiency present in ALK1 HHT mutations, 
opposite to the overexpression usually showed in 
cancers.  
On the other hand, colorectal cancer was instead 
more frequent in younger HHT patients, 
particularly in the subgroup with SMAD4 
mutations and juvenile polyposis. 
Hereditary hemorrhagic 
telangiectasia type 2 (HHT2) 
Note 
Hereditary Hemorrhagic Telangiectasia (HHT), or 
Rendu-Osler-Weber disease, is a vascular dysplasia 
inherited as an autosomal dominant trait (Shovlin, 
2010; McDonald et al., 2011). It affects 
approximately 1 in 5-8000 individuals (Faughnan et 
al., 2011) with regional differences due to founder 
effects (Westermann et al., 2003; Lesca et al., 
2008). The clinical diagnosis of HHT is based on 
the presence of at least three of the following 
"Curaçao criteria" (Shovlin et al., 2000): (1) 
spontaneous, recurrent epistaxis; (2) 
mucocutaneous telangiectases at characteristic sites 
as nose, lips, oral cavity, finger tips and 
gastrointestinal (GI) mucosa; (3) visceral 
arteriovenous malformations (AVMs) in lungs, 
liver, GI, brain and spinal cord; (4) family history 
of first-degree relative in whom HHT has been 
diagnosed using these criteria. Significant clinical 
variability was observed in HHT (Lesca et al., 
2007; Govani and Shovlin, 2009), with both intra- 
and interfamilial variations in age-of-onset, 
localization of lesions, and severity of 
complications, whereas it usually shows a high  
penetrance. HHT is usually not apparent at birth, 
but evolves with age into a recognizable phenotypic 
pattern. Spontaneous recurrent nosebleeds are the 
most common and usually earliest clinical 
manifestation. HHT telangiectases develop and get 
worse with age. Complete penetrance was found to 
be by 40 years of age (Porteous et al., 1992). HHT 
patients show approximately 15-50% of pulmonary 
AVMs (PAVMs), 32-78% of liver AVMs 
(HAVMS) and approximately 23% will harbor 
AVMs in the brain (CAVMs). Although 80% of 
patients with HHT have gastric or small intestinal 
telangiectases, only 25-30% of patients will 
develop symptomatic GI bleeding which usually 
does not present until the fifth or sixth decades of 
life (Faughnan et al., 2011). 
HHT arises from heterozygous mutations in ENG 
(HHT1, OMIM #187300) coding for ENDOGLIN 
(ENG) (McAllister et al., 1994) and ACVRL1 
(HHT2, OMIM #600376) coding for ALK1 
(Johnson et al., 1996), Type III and Type I TGF-β 
receptors, respectively. Certain HHT2 patients 
develop a Pulmonary Artery Hypertension (PAH)-
like syndrome, suggesting that ACVRL1 mutations 
are also likely to be involved in PAH (Trembath et 
al., 2001; Olivieri et al., 2006). A subset of patients 
with juvenile polyposis, carrying mutations in 
SMAD4/MADH4 (JPHT, OMIM #175050), can 
also develop HHT (Gallione et al., 2004). Recently, 
mutations in BMP9 were reported in three unrelated 
families affected by a vascular-anomaly syndrome 
presenting with phenotypic overlap with HHT 
(Wooderchak-Donahue et al., 2013). Additional as-
yet-unknown HHT genes have been suggested by 
linkage analysis in two affected kindred on 
chromosome 5 and on chromosome 7 (Cole et al., 
2005; Bayrak-Toydemir et al., 2006). Molecular 
genetic testing of the three known genes detects 
mutations in approximately 85% of patients. As 
reported above, the mutated genes encode proteins 
that mediate signaling by TGF-β family.  
More than 375 ACVRL1 variants are present in the 
international HHT mutation database and more than 
185 are demonstrated to be pathogenic for HHT. 
TGF-β ligands regulate angiogenesis through their 
actions either on endothelial cells (EC) and/or 
mural cell, demonstrating that they play important 
roles in both activation (via ALK1) and resolution 
(via ALK5) phases of angiogenesis. It has been 
reported that BMP9, rather than BMP10, might be 
the specific ALK1 ligand and activator of the 
Smad1/5/8 signaling pathway in endothelial cells 
and that they are potent inhibitors of EC migration 
and growth (David et al., 2007). Previous studies 
have suggested the synergy between Notch and 
TGF-β, and that Notch signaling modulates the 
balance between TGF-β/ALK1 and TGF-β/ALK5 
signaling pathways (Fu et al., 2009). 
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ALK1-1 and pulmonary arterial 
hypertension 
Note 
Pulmonary arterial hypertension (PAH) is a severe 
and rare disease affecting small pulmonary arteries, 
with progressive remodeling leading to elevated 
pulmonary vascular resistance and right ventricular 
failure, and is a major cause of progressive right-
sided heart failure and premature death (Trembath 
et al., 2001). PAH is defined as the sustained 
elevation of mean pulmonary artery pressure (PA) 
above 25 mmHg at rest or 30 mmHg during 
exercise (Rabinovitch, 2012). The histopathology is 
marked by vascular proliferation/fibrosis, 
remodeling, and vessel obstruction (Chan and 
Loscalzo, 2008). 
In the second World Symposium held in Evian, 
France, in 1998, was proposed a clinical 
classification for pulmonary hypertension. The first 
category was defined PAH and includes two 
subgroups, the first incorporates both the idiopathic 
form (IPAH) that the inherited (HPAH) of the 
disease. The second subgroup includes a number of 
conditions associated with various diseases 
(APAH), including connective tissue diseases, 
human immunodeficiency virus infection, 
congenital heart disease, and portal hypertension 
(Simonneau et al., 2004; Machado et al., 2009). 
Heterozygous mutations in the transforming growth 
factor-β receptor (TGF-β receptor) super family 
have been genetically linked to PAH and likely play 
a causative role in the development of disease. 
Particularly, mutations in the bone morphogenetic 
factor receptor type 2 (BMPR2) gene account for 
approximately 70% of all familial pedigrees of 
PAH (HPAH) and 10-30% of idiopathic PAH cases 
(IPAH) (Chan and Loscalzo, 2008; Machado et al., 
2009). 
Much less commonly (5%) two other members of 
the TGF-β superfamily are also recognized as 
uncommon causes of PAH: activine A receptor type 
II-like kinase 1 (ALK1) and, at significant lower 
frequency, endoglin (ENG) (Harrison et al., 2003). 
Heterozygous mutations of these genes cause the 
autosomal dominant vascular disorder hereditary 
haemorrhagic teleangiectasia (HHT) (Shovlin, 
2010). In fact, in a small proportion of HHT 
patients, was observed a form of pulmonary arterial 
hypertension that is associated with a model of 
precapillary pulmonary hypertension that is 
histopathologically indistinguishable from 
idiopathic form of PAH. Since the publication by 
Trembath et al. in 2001 (Trembath et al., 2001), 
who first reported patients with a mutation in the 
gene ACVRL1 with clinical features of both PAH 
and HHT, subsequently, have been recognized 
several other mutations in the ALK1 gene that seem 
to predispose patients with HHT development of 
PAH. This observation was further confirmed by 
other studies (Olivieri et al., 2006) and extensively 
discussed by Machado et al. (Machado et al., 2009). 
The exact prevalence of PAH in the HHT 
population has not been systematically evaluated, 
but most authors agree that it is a rare complication 
found in less than 1% of HHT patients (Cottin et 
al., 2007). In rare cases, ACVRL1 mutations have 
been reported to cause IPAH or HPAH without 
HHT (Harrison et al., 2003). 
Both ALK1 and BMPR2 belong to the family of 
TGF-β receptors, they have different specific 
ligands but share a common intracellular pathway 
based on the activation of the SMAD proteins 1/5/8 
(Faughnan et al., 2009).  
The formation of an heteromeric complex with 
BMPR2 and ALK1 could at least in part explain 
why any dysregulation of this pathway may 
promote pulmonary endothelial and/or smooth 
muscle cell dysfunction and proliferative 
characteristic of PAH, in subjects carrying mutation 
either in BMPR2 or in ACVRL1 gene.  
Mutations identified in several studies on ALK1 
associated with PAH are all likely to disrupt 
activation of this intracellular pathway and the 
majority of these comprise missense mutations. 
Particularly, mutations in exon 10 of ACVRL1 are 
relevant because they occur in functional domains 
of the receptor within a conserved carboxyl-
terminal region of ALK1 (the non-activating non-
down regulating box) NANDOR BOX (Faughnan 
et al., 2009; Machado et al., 2009).  
Of note, the NANDOR BOX, located from codon 
479 to 489, is necessary for regulation of TGF-β 
signaling, accordingly any alteration may have 
effects on TGF-β-induced receptor signaling 
(Girerd et al., 2010).  
Moreover, recent studies in animal models have 
shown that Alk1 heterozygous mice spontaneously 
develop signs of pulmonary hypertension in the 
early months of life, and with increasing age show 
more occluded vessels and pulmonary vascular 
remodeling, indicating a progression of the disease. 
These mice had also higher ROS levels in adult 
lungs contributing to PAH development compared 
to control mice.  
Whereas Bmpr2 heterozygous mouse model 
requires additional factors, such as hypoxia and 
serotonin or inflammation, to elicit a pulmonary 
hypertensive phenotype (Jerkic et al., 2011). 
Finally, Girerd B. et al. hypothesized that mutated 
ACVRL1 status might be associated with distinct 
PAH phenotypes, as compared with patients PAH 
without ALK1 mutations.  
The authors analyzed clinical, functional 
characteristic, hemodynamic features and outcomes 
for patients with PAH carrying ACVRL1 mutation. 
Of notice, these patients were significantly younger 
at diagnosis (P 
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Pulmonary arterial hypertension is therefore a 
complex disease that involves the interaction 
between genetic predisposition and environmental 
risk factors. The identification of human mutations 
in components of the TGF-β receptor different from 
each other but somehow bound by common 
intracellular signaling pathways, which may lead to 
the development of pulmonary vascular disease, has 
provided important targets for further investigation. 
Hematological malignancies 
Note 
Roughly 80% of non-Hodgkin's lymphomas and 
60% of Hodgin lymphomas express ALK1 in their 
vasculature (Hu-Lowe et al., 2011). The expression 
of ALK1 in haematological cancers was further 
confirmed in an exploratory study on patients 
affected with Acute Myeloid leukemia (AML) 
(Otten et al., 2011).  
Using qRT-PCR, ALK1 was demonstrated to be 
expressed by 82% of patients' samples 
(pretherapeutic bone marrow or peripheral blood 
from 93 patients with newly diagnosed AML). 
Furthermore, formalin-fixed, paraffin-embedded 
trephine bone marrow specimens from two 
arbitrarily selected patients with AML and from 
two patients with non-leukemic reactive changes 
were analyzed for ALK-1 expressions by 
immunohistochemistry. Endothelial cells from two 
AML patients and those with reactive disorders 
were strongly positive and a fraction of AML blasts 
stained positively for ALK-1 in AML bone 
marrows, whereas normal hematopoietic cells were 
negative.  
Anyway, ALK1 alterations, opposite to those in 
ALK5, seemed not to have a significant impact on 
survival. Furthermore, the prevalence of 
haematological cancers in HHT patients as assessed 
by Hosman et al., 2013 showed no difference 
compared to controls. 
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